Full Press Release Details
Cytokines (ICIS) Annual Meeting
Poster Presentation: CUE-401: A Novel TGF-beta/IL-2 Fusion Protein for the Induction & Expansion of FOXP3+ Regulatory T Cells
• About Us
• Pipeline
• News
• Investors
• Contact Us
CUE Positive Sentiment
Cytokines (ICIS) Annual Meeting
Key Takeaway: The Cytokines (ICIS) Annual Meeting highlighted a poster presentation on CUE-401, a novel TGF-beta/IL-2 fusion protein. This innovative therapy aims to induce and expand FOXP3+ regulatory T cells, which could enhance immunotherapeutic strategies. The meeting underscores the potential impact of CUE-401 in the field of immunology.
Price reaction · baseline $23.028 (2025-10-31 close) · 1 other CUE headline(s) in the window, move may be shared
day 0 close
-6.5%
day 1
-6%
day 3 · peak
-6.7%
Market Sentiment Analysis
POSITIVE FACTORS
- Introduction of CUE-401, a novel therapeutic protein.
- Focus on the induction and expansion of regulatory T cells.
- Potential for significant advancements in immunotherapy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+253%
120-day peak, hindsight
Typical move
10.2%
average across 2 past catalysts
Cash runway
~2 mo
High dilution risk
Lead asset
CUE-101
Phase 2 · Head and Neck Squamous Cell Carcinoma
Frequently Asked Questions
What is CUE-401?
CUE-401 is a novel TGF-beta/IL-2 fusion protein designed to induce and expand FOXP3+ regulatory T cells.
What was presented at the Cytokines Annual Meeting?
The meeting featured a poster presentation on CUE-401 and its potential in immunotherapy.
What are FOXP3+ regulatory T cells?
FOXP3+ regulatory T cells are crucial for maintaining immune tolerance and preventing autoimmune diseases.
Why is CUE-401 significant?
CUE-401 could represent a significant advancement in immunotherapy by enhancing regulatory T cell function.